An EAEU GMP certificate is valid for no more than 3 years, but the Inspection Rules set no interval between inspections


From 1 March 2026, medicines for medical use are manufactured in the Russian Federation under the Good Manufacturing Practice (GMP) rules of the Eurasian Economic Union (the EAEU or the Union). This is established by Federal Law No. 61-FZ of 12 April 2010 «On the Circulation of Medicines» (hereinafter 61-FZ). The rule was introduced into 61-FZ by Federal Law No. 304-FZ of 31 July 2025 «On Amendments to Certain Legislative Acts of the Russian Federation» (hereinafter 304-FZ), which applies from 1 March 2026.
Resolution of the Government of the Russian Federation No. 1314 of 3 December 2015 «On Determining the Compliance of Manufacturers of Medicines with the Requirements of Good Manufacturing Practice Rules» (hereinafter Resolution No. 1314) ceased to have effect on 1 March 2026. This was established by Resolution of the Government of the Russian Federation No. 1766 of 8 November 2025 «On Recognizing Certain Acts of the Government of the Russian Federation as Repealed» (hereinafter Resolution No. 1766). Order of the Russian Ministry of Industry and Trade No. 916 of 14 June 2013 «On Approval of the Good Manufacturing Practice Rules» (hereinafter Order No. 916) and Order No. 4148 of 18 December 2015 (hereinafter Order No. 4148), which amended it, were repealed by Order of the Russian Ministry of Industry and Trade No. 3093 of 25 June 2026 (registered by the Russian Ministry of Justice on 28 July 2026 under No. 87651; hereinafter Order No. 3093).
A certificate of compliance of manufacturing with the Union’s GMP requirements is issued following a pharmaceutical inspection. The inspection is conducted under the Rules for Conducting Pharmaceutical Inspections for Compliance with the Requirements of the Union’s Good Manufacturing Practice Rules (hereinafter the Inspection Rules), approved by Decision of the Council of the Eurasian Economic Commission (EEC) No. 83 of 3 November 2016 «On Approval of the Rules for Conducting Pharmaceutical Inspections». Inspections are conducted by a pharmaceutical inspectorate in accordance with a plan (schedule). The term «pharmaceutical inspectorate» is used in the meaning defined in the General Requirements for the Quality System of Pharmaceutical Inspectorates of the Member States of the Eurasian Economic Union, approved by Decision of the EEC Council No. 82 of 3 November 2016.
If inspectors classify the identified deficiencies as critical or major (the definitions are given in the section «Deficiency categories and the certification decision»), the report is prepared in two parts. Part I is signed no later than 30 calendar days after completion of the inspection, and Part II no later than 30 calendar days after the response and documentary evidence of remediation of all deficiencies are submitted. The manufacturer sends the response no later than 60 calendar days after receiving Part I. The response includes a corrective and preventive action (CAPA) plan, a report on its implementation and information on remediation of the deficiencies. If the response is not sent within this period, Part II of the report is prepared on the 61st calendar day, and the manufacturing operations are deemed non-compliant with the Union’s GMP requirements.

What changed on 1 March 2026

Table 1 compares the procedure in effect before 1 March 2026 (under 61-FZ as amended on 23 July 2025 and the Rules approved by Resolution No. 1314 as amended on 5 September 2020, hereinafter the Rules under Resolution No. 1314) with the procedure under the Inspection Rules (as amended on 1 August 2025) as of 19 October 2026.

Table 1. Procedure for issuing a GMP compliance document before and after 1 March 2026

IssueBeforeAfter
Good Manufacturing Practice rulesManufacturing had to comply with GMP rules approved by the authorized federal executive body (61-FZ as amended on 23 July 2025). Those rules were contained in Order No. 916Medicines for medical use are manufactured under the Union’s GMP rules (61-FZ). Order No. 916 and Order No. 4148 have been repealed (Order No. 3093)
Inspection procedureThe procedure for organizing and conducting inspections was established by the Government of the Russian Federation (61-FZ as amended on 23 July 2025). The Rules under Resolution No. 1314 appliedThe procedure is set by the Inspection Rules. Resolution No. 1314 has been repealed (Resolution No. 1766)
Document issued following the inspectionA conclusion in a form approved by the authorized body (Resolution No. 1314)A certificate in the form given in the Inspection Rules
Validity3 years from completion of the inspection (Rules under Resolution No. 1314)No more than 3 years from completion of the inspection; the term may be shortened under risk management principles, with a record in the certificate (Inspection Rules)
Time limits for the inspection and the decision to issue the documentThe inspection was conducted within no more than 160 working days from the decision to conduct it, and the inspection itself took no more than 10 working days, excluding travel time. The decision to issue or refuse the document was taken within 10 working days from signing of the inspection report or its receipt from the authorized institution (Rules under Resolution No. 1314)The Inspection Rules set no maximum time limit for the inspection: the time limits for individual stages are established under the legislation of the member state, taking these Rules into account. The certificate is issued no later than 10 working days from the decision to issue it
Time limit for the reportFor a foreign manufacturer, 25 working days from completion of the inspection. For a manufacturer in Russia, the Rules under Resolution No. 1314 did not name a time limit for preparing the inspection report30 calendar days from completion of the inspection; where critical and major deficiencies are identified, this is the time limit for Part I of the report (Inspection Rules)
Response to deficienciesA foreign manufacturer was entitled to submit a CAPA plan within 60 working days from receipt of the report (Rules under Resolution No. 1314). For a manufacturer in Russia, the Rules under Resolution No. 1314 contained no such mechanismThe response with the CAPA plan, the report on its implementation and information on remediation is sent no later than 60 calendar days from receipt of Part I. Failure to submit the response on time is among the grounds for deeming the manufacturing operations non-compliant (Inspection Rules)
FeeRUB 7,500 for issuing a conclusion (Resolution No. 1314)61-FZ (as amended on 4 August 2026) instructs the Government of the Russian Federation to set a fee for issuing certificates (conclusions) for medicines for veterinary use. For medicines for medical use, 61-FZ does not name a fee for issuing a certificate. The fee for the inspection service is determined under Order of the Russian Ministry of Industry and Trade No. 90 (see the section «How much an inspection costs»)

Conclusions on a manufacturer’s compliance with GMP requirements, issued as documents before 1 March 2026, remain valid until their validity period ends (under 304-FZ). Resolution No. 1766 takes effect on 1 March 2026 without transitional provisions. 304-FZ, Resolution No. 1766 and the Inspection Rules contain no provisions on applications filed before 1 March 2026 or on inspections begun before that date.

Who issues the certificate and which procedures require it

A Russian manufacturer receives a certificate during licensing of the manufacture of medicines for medical use, including periodic confirmation of the licensee’s compliance with licensing requirements (under 61-FZ). Manufacturing is licensed by the Russian Ministry of Industry and Trade under the Regulation on the Licensing of the Manufacture of Medicines, approved by Resolution of the Government of the Russian Federation No. 686 of 6 July 2012 (hereinafter the Licensing Regulation). The certificate is issued if the licensing procedure has a positive result and a decision is taken to grant a license or to amend the register of licenses. Compliance of manufacturing with the Union’s GMP requirements is among the licensing requirements for a license applicant and for a licensee.
The Russian Ministry of Industry and Trade organizes and conducts pharmaceutical inspections of the manufacture of medicines for medical use for compliance with the Union’s GMP requirements, including jointly with the pharmaceutical inspectorates of another member state. This follows from the Regulation on the Ministry of Industry and Trade of the Russian Federation, approved by Resolution of the Government of the Russian Federation No. 438 of 5 June 2008 (as amended on 11 June 2026; hereinafter the Regulation on the Ministry). The Russian Ministry of Industry and Trade also issues certificates, suspends, resumes and terminates their validity and amends them. These powers of federal executive bodies are named in 61-FZ. Under 61-FZ, the procedure for maintaining the state register of certificates (conclusions) of compliance of manufacturing with the Union’s GMP requirements, and maintaining the register itself, also fall within the powers of federal executive bodies.
Periodic confirmation of a licensee’s compliance with licensing requirements is carried out every three years from the date the license is granted, unless the licensing regulation provides for a longer period (under Federal Law No. 99-FZ of 4 May 2011 «On the Licensing of Certain Types of Activities», hereinafter 99-FZ). The manufacture of medicines is among the activities to which 99-FZ applies periodic confirmation. The Licensing Regulation sets no longer period. The application for confirmation is filed no earlier than one year before the due date. The total duration of the procedure does not exceed twenty working days from the day the application is accepted.
Following the procedure, the licensing authority decides either that the licensee complies or to send a list of identified violations with a deadline for remedying them. For confirmation relating to the manufacture of medicines for medical use, a report is drawn up in the form set by the Inspection Rules. A licensing regulation may set the time limit and procedure for remedying violations, but the Licensing Regulation sets no such time limit. Neither 99-FZ nor the Licensing Regulation determines how the response deadline under the Inspection Rules relates to the deadline for remedying violations that the licensing authority gives in its list.
When applying for registration of a medicinal product, confirmation of registration (renewal) and dossier alignment with Union requirements, the applicant submits as part of the dossier a valid document on GMP compliance with the Union’s requirements for the site where the finished dosage form is manufactured and release quality control is carried out. This requirement is contained in the Rules for Registration and Regulatory Review of Medicines for Medical Use, approved by Decision of the EEC Council No. 78 of 3 November 2016 «On the Rules for Registration and Regulatory Review of Medicines for Medical Use» (hereinafter the Registration and Review Rules). Instead of this document, the applicant may submit, until its validity period ends, a GMP compliance document issued by the authorized body of a member state. If a valid document cannot be submitted, the applicant submits the following in its place when applying for registration or dossier alignment: valid documents of the country of manufacture; a copy of the report on the latest inspection carried out within the last 3 years; information on the results of all inspections and on complaints over 3 years; consent to a pharmaceutical inspection for compliance with the Union’s GMP requirements; and a copy of the site master file (the manufacturing site dossier). An inspection initiated at registration is conducted by the inspectorate of the state determined under the Registration and Review Rules.

How the inspection is conducted

An entity subject to inspection is an organization that manufactures medicines and holds an authorization (license) for that activity issued by the authorized body of the country of manufacture.
Under the Inspection Rules, the inspection procedure consists of nine stages:
receipt and review of the documents submitted;
agreeing the inspection dates with the entity subject to inspection or its representative;
forming the inspection team;
preparing and sending the inspection program;
inspecting the site, including sampling and laboratory testing of samples where necessary;
preparing the report;
assessing the CAPA plan, the report on its implementation and evidence of remediation of deficiencies, where necessary;
the decision to issue or refuse to issue the certificate;
issuing the certificate.

The inspection team consists of a lead inspector and inspectors, no fewer than two pharmaceutical inspectors in all. A resident, that is, a manufacturing organization in the territory of a member state, submits an application for an inspection and a copy of the site master file (SMF), together with a copy of the license if there is one. The site master file is prepared under the Good Manufacturing Practice Rules of the Union, approved by Decision of the EEC Council No. 77 of 3 November 2016 «On Approval of the Good Manufacturing Practice Rules of the Eurasian Economic Union» (hereinafter the GMP Rules). A resident also submits a list of medicines manufactured or planned for manufacture at the site, in the form given in the Inspection Rules.
A non-resident, that is, a manufacturing organization whose manufacturing site is located in a third country, submits an application for an inspection, a copy of the site master file and a list of medicines manufactured or planned for manufacture at the site. In addition, a non-resident submits a certified copy of a valid authorization (license) for the manufacture of medicines issued by the authorized body of that country, or an extract from its register. A non-resident also submits, if it has one, a certified copy of the document issued by the authority of the country of manufacture on compliance with the GMP requirements applied in that country. Documents are submitted in Russian and (or) in the state language of the member state, if its legislation requires this, or in translation into those languages.
An inspection may be refused if the information in the application or in documents submitted on request is incomplete or inaccurate, if the applicant has not provided the conditions for inspection and the procedure cannot be carried out, or if the inspection expenses are not paid within the established period, where this applies.
The lead inspector prepares the inspection program in the form given in the Inspection Rules and sends it to the entity subject to inspection no later than 10 working days before the start date. The entity subject to inspection designates a person responsible for assisting with the inspection.
The contract or agreement between the inspectorate and the entity subject to inspection must reflect, among other things, the following rights of the inspector:
access to any premises under the inspection program and to the site master file;
obtaining evidence, such as documentation and photo and video materials of premises and equipment;
access to any object within the scope of the inspection and its examination;
measures, or a requirement for measures, in respect of items that may indicate non-compliance;
inspecting objects, reviewing documentation and records, questioning responsible persons and observing work at workplaces;
terminating the inspection if these rights are obstructed.

Under the contract, the entity subject to inspection undertakes to ensure that the actions provided for in the program can be carried out.
At the end of each day, the lead inspector holds a meeting with the team and, where necessary, discusses preliminary observations with the responsible persons of the entity subject to inspection. The lead inspector immediately informs those persons of deficiencies that are planned to be classified as critical. At the closing meeting, the preliminary results are announced and the identified deficiencies are discussed, so that a CAPA plan can subsequently be prepared where necessary.

Time limits for the inspection and the report

Table 2. Time limits under the Inspection Rules

StageTime limit
Sending the inspection program to the entity subject to inspectionNo later than 10 working days before the inspection start date
Report where there are no deficiencies or only other deficienciesSigned no later than 30 calendar days from completion of the inspection
Part I of the report where there are critical and (or) major deficienciesSigned no later than 30 calendar days from completion of the inspection
Response of the entity subject to inspection (CAPA plan, implementation report, information on remediation)No later than 60 calendar days from receipt of Part I
Part II of the reportSigned no later than 30 calendar days from the date the response and documentary evidence of remediation of all deficiencies are submitted, and where the response is not submitted on time, on the 61st calendar day from the date the entity subject to inspection receives Part I
Sending the report (Part I or Part II) to the entity subject to inspectionNo later than 3 working days from signing
Issuing the certificateNo later than 10 working days from the decision to issue it
Notification of refusal to issue the certificateNo later than 10 working days from the date of the decision to refuse
Amendments to the certificate without an inspectionNo more than 20 working days from the date the application is filed
Notification of suspension or termination of the certificate where there are critical deficienciesNo later than 5 working days from completion of the inspection

If samples were taken, the time limit for preparing the report runs from the date the lead inspector receives the test results.

Deficiency categories and the certification decision

The report form given in the Inspection Rules divides deficiencies into three categories.
Critical deficiencies cause or give rise to a significant risk of manufacturing a medicine that is hazardous to human health and life.
Major deficiencies cannot be classified as critical but fall into one of the following groups:
they have led or may lead to the manufacture of a medicine that does not comply with the documents of that product’s registration dossier;
they indicate a major deviation from the GMP Rules;
they indicate a major deviation from the requirements of other acts in the sphere of the circulation of medicines;
they indicate the inability of the entity subject to inspection to manufacture products of consistent quality in series, or the inability of its authorized person to perform their duties;
they make up a combination of deficiencies, none of which is major on its own but which together amount to a major deficiency; inspectors must explain such a combination and record it as a major deficiency.

Other deficiencies cannot be classified as critical or major but indicate a deviation from the requirements of the GMP Rules.

Manufacturing is deemed compliant with the GMP Rules in one of the following cases: there are no deficiencies; there are no critical or major deficiencies; or all critical and major deficiencies have been remedied according to the assessment of the response. Manufacturing is deemed non-compliant in one of the following cases:
the report establishes critical and (or) major deficiencies;
critical and major deficiencies have not been remedied according to the assessment of the response;
the response is not submitted within the period set by the Inspection Rules;
the inspector was obstructed in exercising their rights under the contract with the inspectorate (they are listed in the section «How the inspection is conducted»).

The provisions of the Inspection Rules on when manufacturing is deemed compliant or non-compliant, and on the time limit for sending the response, allow two readings. Under the first reading, manufacturing is deemed non-compliant when critical or major deficiencies are established in the report. Under the second reading, manufacturing is deemed compliant when all such deficiencies are remedied according to the assessment of the response: the inspection team assesses the response, and the entity subject to inspection sends it within a period of up to 60 calendar days. The Inspection Rules do not determine how these provisions relate to each other.
The Inspection Rules provide a single ground for refusing to issue a certificate. This is a finding that manufacturing does not comply with the requirements of the GMP Rules. The authorized body (in Russia, the Russian Ministry of Industry and Trade) notifies the entity subject to inspection of the refusal under the procedure established by the legislation of the member state and no later than 10 working days from the date of the decision.
The inspection team takes information on remediation of deficiencies during the inspection into account and records it in the report as deficiencies with a note that they were remedied during the inspection. If only other deficiencies are identified, the team assesses the CAPA plan and the report on its implementation at the next inspection.

Certificate validity and inspection frequency

The validity period of the certificate may not exceed 3 years from completion of the inspection. The period can be shortened by applying risk management principles under the inspectorate’s quality system if the certificate contains a corresponding record. The certificate reflects the status of the site for the period of the inspection and covers the dosage forms and manufacturing operations specified in it.
Inspections are conducted under a plan (schedule), planning may be based on risk management principles, and the Inspection Rules set no numeric frequency. Recommendation of the EEC Board No. 27 of 14 October 2025 «On the Guideline on Risk-Based Planning of Pharmaceutical Inspections for Compliance with the Requirements of the Good Manufacturing Practice Rules of the Eurasian Economic Union» (hereinafter Recommendation No. 27) recommends that member states, after 30 calendar days from the date of publication on the official website of the Union, take the attached Guideline (hereinafter the Guideline) into account when assessing risks related to inspection planning. The Recommendation was published on 17 October 2025; the recommended date for beginning its application is 16 November 2025.
The Guideline does not apply to:
the conduct of inspections;
planning inspections for initial licensing and for amendments to a manufacturing license, where a substandard (falsified) medicine is identified, and in other cases related to control and supervision activities in the sphere of the circulation of medicines;
inspection of sites that have not been inspected before;
planning inspections ordered at registration.

The rating of a site (A, B or C) is made up of two risks: intrinsic risk and the risk of non-compliance with the GMP Rules. Intrinsic risk is determined by the complexity and criticality of the site, and each factor is given 1, 2 or 3 points. The risk of non-compliance is based on the results of the last inspection carried out as scheduled, taking into account the number and classification of deficiencies. The risk of non-compliance is high at 1 or more critical deficiencies or more than 5 major deficiencies, medium when from 1 to 5 major deficiencies are identified, and low when there are no critical or major deficiencies.
The recommended frequency of inspections is every 2-3 years for sites rated A, every 1-2 years for sites rated B, and at least once a year for sites rated C. The actual frequency within a rating depends on the number and classification of deficiencies identified at the last inspection. Sites with a high risk of non-compliance should be inspected again based on the results of implementation of the CAPA plan.
The manufacturer’s response to the last report is treated as new information. The inspectorate may decide that individual information from the response is to be checked thoroughly at the next inspection, and this decision affects the scope of the next inspection. The rating is also reviewed when there is new information on quality defects, product recalls, test results, investigations and changes at the site. The Guideline does not determine the validity period of the certificate.

Suspension, termination and amendment of the certificate

If a risk to the life and health of the population is identified, including potential critical deficiencies, the lead inspector immediately informs the head of the inspectorate and the head of the entity subject to inspection. The head of the inspectorate is informed by telephone, e-mail or another means of communication within 24 hours from the moment the deficiency is identified. Where necessary, the lead inspector takes the actions provided for by the quality system of the member state’s inspectorate, in accordance with the procedure for critical deficiencies (it is described in the next paragraph).
Where critical deficiencies are identified, the inspectorate sends a written notification to the authorized body of the member state. The authorized body may decide to suspend or terminate the validity of a previously issued certificate and, no later than 5 working days from completion of the inspection, notifies the entity that was inspected, the authorized bodies of the other member states and the EEC of this in writing.
The validity of a suspended certificate is resumed:
following review of the CAPA plan, the report on its implementation and evidence of remediation of deficiencies;
on receipt from the authorized body of another member state of information following its review of those documents.

The validity of a previously issued certificate is terminated in the following cases:
the entity subject to inspection refuses to undergo an inspection at the request of the authorized body;
the entity subject to inspection does not ensure that an inspection is conducted at the request of the authorized body;
the authorized body of the member state whose inspectorate conducted the inspection, or the authorized body of another member state, refuses to issue the certificate.

Amendments that do not require an inspection are made to the certificate on application with documents confirming the need for the amendments, in no more than 20 working days from the date the application is filed. Such amendments are a change of the name of the legal entity or manufacturing site, of the legal form, or of the address without a change of the actual location of the site, and the correction of typographical errors. The certificate number, the date (period) of the inspection and the validity period remain unchanged. Information on certificates issued, suspended, resumed and terminated and on amendments made is placed in the databases of the authorized bodies of the member states and in the integrated information system of the Union. The inspectorate considers complaints about inspection results under the procedure and within the time limits set by its quality system and the legislation of the member states.

Remote inspection

An inspection using remote interaction tools is allowed in special cases. The inspectorate takes this decision in the event of a threat of an emergency, an emergency or the elimination of an emergency, a threat of the spread of epidemic diseases dangerous to others, or a threat of diseases and injuries caused by adverse chemical, biological or radiation factors. The Inspection Rules also name force majeure or circumstances beyond the control of the parties that threaten the life and health of inspectors, for example for political, medical or other reasons. The Guideline also allows remote inspection in cases not named in the Inspection Rules if the overall risk rating of the site is determined as low.
A remote inspection is conducted under the procedure included in the Inspection Rules. The inspectorate takes the decision on it under the risk criteria of its quality system. If the decision is taken, the entity subject to inspection submits additional documents and information from the list in that procedure. The entity subject to inspection may omit these documents if it sends a letter stating that they are contained in the site master file and were up to date at the time the application was filed.
Before the inspection begins, the entity subject to inspection confirms the geolocation data of the site. On notification from the inspectorate, the entity subject to inspection arranges a technical test of the connection. The entity subject to inspection places the documents in electronic form, with a translation into Russian or English, in cloud storage or in another agreed way.
Recording the videoconference and the materials presented during the inspection is not allowed without the consent of the entity subject to inspection. At the end of each day, the inspectors send a list of questions and a list of the documentation needed by e-mail. The entity subject to inspection submits the documentation named at the closing meeting within 5 working days from the end of the inspection or within another agreed period.
The report and the certificate state that the inspection was remote. An on-site inspection must be conducted after the restrictions are lifted, taking into account the validity period of that certificate. For sites inspected for the first time, if 1 or more critical or more than 5 major deficiencies are identified, the subsequent inspection is conducted on site.

How much an inspection costs

The expenses of an inspection are borne by the entity subject to inspection or its authorized representative. The fee is determined under the methodologies (hereinafter the Methodologies) approved by Order of the Russian Ministry of Industry and Trade No. 90 of 20 January 2021 (hereinafter Order No. 90). Under the Methodologies, assessment of the CAPA plan and the report on its implementation is a separate service, formalized by a supplementary agreement.
The maximum fees are set by Order No. 90 as amended on 25 June 2025 (Table 3). The fee is reviewed once a year, before 1 September of the current financial year, and also when regulatory legal acts change. As of 19 October 2026, the latest version of Order No. 90 that was checked is dated 25 June 2025.

Table 3. Maximum fees under Order No. 90 (as amended on 25 June 2025)

SiteInspectionWhere a CAPA plan and a report on its implementation are received
In the Russian FederationRUB 2,965,466.37 including business trip expenses and 20% VATRUB 1,120,602.18 including 20% VAT
Outside the Russian Federation, including jointly with the inspectorate of another member stateRUB 4,734,277.05 including business trip expenses and 20% VATRUB 1,241,222.54 including 20% VAT

Material costs not included in the calculation are paid by the applicant; the fee, including those costs, must not exceed the maximum amount. The entity subject to inspection sends samples for testing to a laboratory determined under the legislation of the member state, and the cost of the samples is not reimbursed to it. It also bears the costs of transporting samples, customs operations and customs control for samples moved across the customs border of the Union, and the costs of testing the samples.

What to do

Identify the procedure for which you need the certificate and put the deadline in your calendar. For a Russian manufacturer, find the date the license was granted, count three years and file the application for periodic confirmation no earlier than one year before the deadline. Under 99-FZ, failure to file the application, as a result of which the confirmation cannot be carried out before the deadline, is among the grounds for suspending the license. If the certificate is needed for registration or dossier alignment with Union requirements, check which GMP document of the Union you have and, if you have none, assemble the set of documents under the Registration and Review Rules.
Assemble the set of documents for the inspection. Prepare the application, the site master file under the GMP Rules, the list of medicines (for a resident, in the form given in the Inspection Rules) and a Russian translation; for a non-resident, add the documents of the third country. Pay the expenses within the established period, because non-payment is among the grounds for refusing an inspection. Calculate the budget under Order No. 90 and check it against Table 3.
Prepare for the inspection program. Designate a person responsible for assisting with the inspection, check that the contract reflects the inspector’s rights, and prepare documents by section of the program, which you will receive no later than 10 working days before the start. Each evening, review the preliminary observations with the inspectors and record what has been remedied on site: such deficiencies remain in the report with a note that they were remedied.
Count 60 calendar days from receipt of Part I of the report and prepare three documents. The response consists of the CAPA plan, the report on its implementation and the information on remediation of the deficiencies. Send the package before this period ends: without a response, Part II of the report is prepared on the 61st calendar day, and the manufacturing operations are deemed non-compliant.
After the certificate is issued, check the document and set the dates of expiry and of the next inspection. Make sure the certificate names the dosage forms and operations you need and has no record of a shortened term. The validity period does not exceed 3 years from completion of the inspection, and where a shortening is recorded, set the date from that record. If the name, legal form or address changes without relocation, file an application to amend the certificate. Plan the date of the next inspection taking into account the rating of the site and the fact that the response to the report may affect the scope of the next inspection.


Regulatory framework:

1. Federal Law No. 61-FZ of 12 April 2010 «On the Circulation of Medicines» (as amended on 4 August 2026; the version of 23 July 2025 was used in Table 1 for the procedure before 1 March 2026)
2. Federal Law No. 304-FZ of 31 July 2025 «On Amendments to Certain Legislative Acts of the Russian Federation» (as amended on 4 August 2026)
3. Federal Law No. 99-FZ of 4 May 2011 «On the Licensing of Certain Types of Activities» (as amended on 4 August 2026)
4. Resolution of the Government of the Russian Federation No. 686 of 6 July 2012 «On Approval of the Regulation on the Licensing of the Manufacture of Medicines» (as amended on 25 December 2025), including the Regulation on the Licensing of the Manufacture of Medicines approved by it
5. Resolution of the Government of the Russian Federation No. 1314 of 3 December 2015 «On Determining the Compliance of Manufacturers of Medicines with the Requirements of Good Manufacturing Practice Rules» (as amended on 5 September 2020, ceased to have effect on 1 March 2026), including the Rules approved by it for Organizing and Conducting Inspections of Manufacturers of Medicines for Compliance with the Requirements of Good Manufacturing Practice Rules, and for Issuing Conclusions on the Compliance of a Manufacturer of Medicines with These Requirements
6. Resolution of the Government of the Russian Federation No. 1766 of 8 November 2025 «On Recognizing Certain Acts of the Government of the Russian Federation as Repealed»
7. Resolution of the Government of the Russian Federation No. 438 of 5 June 2008 «On the Ministry of Industry and Trade of the Russian Federation» (as amended on 11 June 2026), including the Regulation on the Ministry of Industry and Trade of the Russian Federation approved by it
8. Order of the Russian Ministry of Industry and Trade No. 3093 of 25 June 2026 «On Recognizing as Repealed Order No. 916 of the Ministry of Industry and Trade of the Russian Federation of 14 June 2013 ‘On Approval of the Good Manufacturing Practice Rules’ and the Amendments Made to It» (registered by the Russian Ministry of Justice on 28 July 2026 under No. 87651)
9. Decision of the EEC Council No. 83 of 3 November 2016 «On Approval of the Rules for Conducting Pharmaceutical Inspections» (as amended on 1 August 2025), including the Rules approved by it for Conducting Pharmaceutical Inspections for Compliance with the Requirements of the Good Manufacturing Practice Rules of the Eurasian Economic Union
10. Decision of the EEC Council No. 78 of 3 November 2016 «On the Rules for Registration and Regulatory Review of Medicines for Medical Use» (as amended on 26 November 2025)
11. Decision of the EEC Council No. 77 of 3 November 2016 «On Approval of the Good Manufacturing Practice Rules of the Eurasian Economic Union» (as amended on 4 July 2023)
12. Decision of the EEC Council No. 82 of 3 November 2016 «On Approval of the General Requirements for the Quality System of Pharmaceutical Inspectorates of the Member States of the Eurasian Economic Union»
13. Recommendation of the EEC Board No. 27 of 14 October 2025 «On the Guideline on Risk-Based Planning of Pharmaceutical Inspections for Compliance with the Requirements of the Good Manufacturing Practice Rules of the Eurasian Economic Union»
14. Order of the Russian Ministry of Industry and Trade No. 90 of 20 January 2021 «On Approval of the Methodologies for Determining the Fee for Services for Conducting Pharmaceutical Inspections of the Manufacture of Medicines for Medical Use Located in the Russian Federation for Compliance with the Requirements of the Good Manufacturing Practice Rules of the Eurasian Economic Union, and for Conducting Pharmaceutical Inspections of the Manufacture of Medicines for Medical Use Located Outside the Russian Federation for Compliance with the Requirements of the Good Manufacturing Practice Rules of the Eurasian Economic Union, Including Jointly with the Pharmaceutical Inspectorates of Another Member State of the Eurasian Economic Union, for the Purpose of Issuing a Certificate (Certificates) of Compliance of a Manufacturer (Manufacturers) of Medicines for Medical Use with the Requirements of the Good Manufacturing Practice Rules of the Eurasian Economic Union, and the Maximum Amount of Fees for These Services» (as amended on 25 June 2025)
15. Order of the Russian Ministry of Industry and Trade No. 916 of 14 June 2013 «On Approval of the Good Manufacturing Practice Rules» (repealed; see Order No. 3093)
16. Order of the Russian Ministry of Industry and Trade No. 4148 of 18 December 2015 «On Amendments to Order No. 916 of the Ministry of Industry and Trade of the Russian Federation of 14 June 2013 ‘On Approval of the Rules for the Organization of the Manufacture and Quality Control of Medicines’» (repealed; see Order No. 3093; title as given in Order No. 3093)

This page in Russian→